Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OTS 167

Next Previous
Drug Profile

OTS 167

Alternative Names: OTS 167PO; OTS-167; OTSSP167

Latest Information Update: 10 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoTherapy Science
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MELK protein inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Breast cancer; Triple negative breast cancer
  • Preclinical Diamond-Blackfan syndrome
  • No development reported Multiple myeloma; Ovarian cancer; Renal cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 06 Dec 2025 Pharmacodynamics data from a preclinical study in Diamond-Blackfan syndrome presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 09 Dec 2023 Preclinical trials in Diamond-Blackfan syndrome in Japan (unspecified route)
  • 09 Dec 2023 Pharmacodynamics data from a preclinical studies in Diamond-Blackfan syndrome presented at the ( 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top